world
'Solengepras' Pill Targets GPR6 Receptor In The Brain | WION News
WION
October 8, 2026
via WIONYou're reading one story from Newsaly
Newsaly brings together 60,000+ newspaper articles, 30,000+ podcasts and 10,000+ magazine articles from around the world.
A World Of News, One Window.
Explore Today's News
Solengepras (CVN424) is an investigational, once-daily oral treatment for Parkinson’s disease developed by US biopharmaceutical company Cerevance. Unlike traditional dopamine-based therapies such as levodopa, solengepras targets the brain’s GPR6 receptor and works independently o
Read the full story
Explore More On Newsaly
Voices (0)
Share a 15-second voice reaction. Voices automatically disappear after 10 days.
Sign in to record a voice on this article.
Be the first to share a voice on this article.